SCHEMBL6760148

SCHEMBL6760148

CCOC(=O)C1(C(=O)OCC)CCC2(CC1)NCCc1cc(OC)c(OC)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
KCNK3 O14649 1/20 0.35
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
HIF1A Q16665 1/20 0.33
EPAS1 Q99814 1/20 0.33
OPRM1 P35372 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759721 0.88 OPRM1 (0.32) KMT2AKDM4EALDH1A1OPRM1CYP3A4
SCHEMBL6761417 0.86 ALDH1A1 (0.47) KMT2AKDM4EALDH1A1HIF1AEPAS1
SCHEMBL6761606 0.84 CYP2C19 (0.39) KMT2AKDM4ELMNAALDH1A1HPGD
SCHEMBL6757334 0.83 KMT2A (0.49) KMT2AALDH1A1KCNK3CYP2C9CYP2C19
SCHEMBL6761571 0.81 ESR2 (0.40) KMT2AKDM4ELMNAALDH1A1OPRM1
SCHEMBL6760152 0.77 OPRM1 (0.33) KMT2AOPRM1
SCHEMBL6757323 0.75 PKM (0.38) KMT2AKDM4EALDH1A1PKMCYP1A2
SCHEMBL6757328 0.75 PKM (0.38) KMT2AKDM4EALDH1A1PKMCYP1A2
SCHEMBL6764415 0.73 RAD52 (0.36) KMT2AKDM4ELMNAALDH1A1PKM
SCHEMBL6757305 0.72 KDM4E (0.37) KMT2AKDM4EALDH1A1PKMKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106635-A1 having small-conductance potassium channel (SK) blocking activity TANABE SEIYAKU CO., LTD. (JP) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106635-A1 having small-conductance potassium channel (SK) blocking activity KCNN1, KCNN2, KCNN3 KMT2A 1633/4885KDM4E 1346/4885LMNA 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.